Cancer-Fighting mRNA tech tested in patients out of options
NCT ID NCT07332663
Summary
This early-stage study is testing a new experimental drug called WGb-0301 for people with advanced B-cell cancers (like certain leukemias and lymphomas) that have come back or stopped responding to standard treatments. The drug uses mRNA technology—similar to that in some COVID-19 vaccines—packaged in tiny fat particles to target and potentially clear cancerous B-cells. The main goals are to find a safe dose and see if the treatment shows any signs of helping control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.